Back
NovoCure Ltd. 10K Form
Sell
36
NVCR
NovoCure Ltd.
Last Price:
$11.90
Seasonality Move:
-1.74%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-10-26 | 10Q | NVCR/NovoCure Ltd. Quarterly |
| 2023-07-27 | 10Q | NVCR/NovoCure Ltd. Quarterly |
| 2023-05-04 | 10Q | NVCR/NovoCure Ltd. Quarterly |
| 2022-10-27 | 10Q | NVCR/NovoCure Ltd. Quarterly |
| 2022-07-28 | 10Q | NVCR/NovoCure Ltd. Quarterly |
| 2022-04-28 | 10Q | NVCR/NovoCure Ltd. Quarterly |
Receive NVCR News And Ratings
See the #1 stock for the next 7 days that we like better than NVCR
NVCR Financial Statistics
Sales & Book Value
| Annual Sales: | $605.2M |
|---|---|
| Cash Flow: | $14.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $3.05 |
| Price / Book: | 3.86 |
Profitability
| EPS (TTM): | -1.61170 |
|---|---|
| Net Income (TTM): | $-177.7M |
| Gross Margin: | $469M |
| Return on Equity: | -50.08% |
| Return on Assets: | -14.06% |
NovoCure Ltd. Earnings Forecast
Key NovoCure Ltd. Financial Ratios
-
The Gross Profit Margin over the past 12 years for NVCR is 77.50%.
-
The Selling, General & Administrative Expenses for NVCR have been equal to 70.87% of Gross Profit Margin.
-
The Research & Development expenses have been 34.59% of Revenue.
-
The Net Earning history of NVCR is -27.86% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 7 years.
NovoCure Ltd. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Health Care Equipment & Supplies |
| Sector: | Health Care |
| Current Symbol: | NVCR |
| CUSIP: | G6674U |
| Website: | novocure.com |
Debt
| Debt-to-Equity Ratio: | 2.34 |
|---|---|
| Current Ratio: | 1.55 |
| Quick Ratio: | 1.44 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
NVCR Technical Analysis vs Fundamental Analysis
Sell
36
NovoCure Ltd. (NVCR)
is a Sell
Is NovoCure Ltd. a Buy or a Sell?
-
NovoCure Ltd. stock is rated a SellThe current NovoCure Ltd. [NVCR] share price is $11.76. The Score for NVCR is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.